Plain-English translation of NCT07405216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called dapagliflozin to see if it can help protect the kidneys of teenagers with early-stage kidney disease who have protein leaking into their urine. Researchers want to know if this treatment is safe and effective in young people—it has shown promise in adults, but teenagers have rarely been included in these studies before. You would receive either the medication or a placebo (a pill with no active ingredient) every day for the duration of the trial.
In the Aguascalientes region of Mexico, kidney disease affects many teenagers and young adults at unusually high rates. This medication has shown promise in slowing kidney disease in adults, but no one has carefully studied whether it works safely in teenagers with early-stage disease, so researchers are conducting this trial to fill that gap.
You likely qualify if…
You likely don't qualify if…
You would take either the study medication or a placebo pill once daily and attend regular clinic visits for screening, baseline evaluations, and follow-up appointments. During these visits, you would have blood and urine tests to monitor your kidney function and protein levels, and researchers would check how well the treatment is working and whether you are having any side effects. The trial is randomized, meaning you would be randomly assigned to receive either the medication or the placebo, and it is double-blind, meaning neither you nor your doctors would know which one you are taking until the study ends.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Mexico